Learn about BYDUREON, a non-insulin treatment option for adults with type 2 diabetes available in the BYDUREON Pen. Find dosing and administration information for BYDUREON, including instructions for use. Learn about BYDUREON® BCise® including efficacy, safety, PK profile, and dosing, and available resources, including Important Safety Information.
|Published (Last):||8 November 2007|
|PDF File Size:||6.11 Mb|
|ePub File Size:||17.55 Mb|
|Price:||Free* [*Free Regsitration Required]|
Bydureon (exenatide) dose, indications, adverse effects, interactions from
Therefore, the use of exenatide is not recommended in patients with severe GI disease e. While still holding the autoinjector upright, unscrew the orange cap.
Patients at risk include those with compromised renal function, those fasting for prolonged periods, those that are malnourished, and those receiving high or excessive doses of sulfonamides. It is unclear if hemoglobin A1C is improved or if improvements are sustained with continued treatment beyond 24 weeks.
A reduction in dose of oral hypoglycemic medications may be required in some patients taking orlistat. Animal reproduction studies identified increased adverse fetal and neonatal outcomes from exposure to exenatide during pregnancy and lactation, in association with maternal effects.
In patients with type 2 diabetes, exenatide moderates glucagon secretion and lowers serum glucagon concentrations during periods of hyperglycemia. Although specific dose recommendations are not available for most agents, the clinician should consider a dose reduction of the insulin secretagogue or insulin when used in combination with exenatide.
When possible it may be prudent to take any oral medication at least 1 hour prior to administration of injectable exenatide, although specific research addressing this issue is not available. To avoid potential pharmacokinetic interactions that packaye alter effectiveness of acetaminophen, it may be advisable for patients to take acetaminophen at least 1 hour prior to an exenatide injection.
According to OBRA, the use of antidiabetic medications should include monitoring e. We do not record any personal information entered above.
The dosing of antidiabetic agents may bydurekn adjustment and blood glucose should be closely monitored when coadministered with tegaserod. Burns, diarrhea, fever, infection, surgery, thyroid disease, trauma, vomiting. Major Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the incretin mimetics, are coadministered.
Monitor blood glucose and for changes in glycemic control and be alert for evidence of an interaction.
Ethinyl Estradiol; Norethindrone; Ferrous fumarate: Exenatide is given via subcutaneous pacoage. Occupation of the GLP-1 receptor site by exenatide results in an increase in both glucose-dependent synthesis of insulin, and in vivo secretion of insulin from pancreatic beta cells in the presence of elevated glucose. The dosing of antidiabetic agents may require adjustment in patients who receive metoclopramide.
Do not substitute needles or any other components in the tray. Diabetic patients must follow a regular, prescribed diet and exercise schedule to avoid either hypo- or hyperglycemia.
For treatment of cold symptoms, nasal decongestants may be preferable for short term, limited use 1 to 3 days as an alternative to systemic decongestants in patients taking medications for diabetes. Ensure the medicine is mixed evenly; rotate and shake or tap as directed until there is no white medicine visible on sides of the pen or syringe. The effect of exenatide to slow gastric emptying may reduce the extent and rate of absorption of orally administered drugs.
Do not share pens among multiple patients in an inpatient setting; use multidose vials instead if available, or, reserve use of any pen to 1 patient only. Based on animal reproduction studies, there may be risks to the fetus from exposure to exenatide during pregnancy, therefore, exenatide should only be used during pregnancy if the potential benefit justifies the potential risk to insrrt fetus.
Moderate Monitor blood glucose levels regularly in patients with diabetes, especially when pasireotide treatment is initiated or when the dose is altered. If a patient chooses to ingest alcohol, they should monitor their blood glucose frequently.
After injection, properly dispose of the pen and needles. Moderate Monitor patients receiving antidiabetic agents closely for worsening glycemic control when corticosteroids are instituted and for pakcage of hypoglycemia when corticosteroids are discontinued.
Do not administer after meals. Use is not recommended. It is unknown whether extended-release exenatide causes thyroid C-cell tumors, including medullary thyroid carcinoma MTCin humans. Administer at any time of day, with or without meals. Exenatide has been studied in patients 65 years of age or older during clinical trials; safety and efficacy were not different in older adult patients versus younger adult patients.
These are available at www. The Cmax values increased less than proportionally over the same range. Initially, 5 mcg subcutaneously twice daily given within the minute period before the morning and evening meal. Inhibitors of MAO type A have been shown to prolong the bydugeon response to insulin and oral sulfonylureas.
Patients with diabetes should inform their health care professionals of their intent to ingest garlic dietary supplements.
An insulin glargine dose titration algorithm is in the exenatide package insert. Fibric acid derivatives may enhance the hypoglycemic bydueon of antidiabetic agents through increased insulin sensitivity and decreased glucagon secretion.
Other symptoms, bydjreon headache, dizziness, nervousness, mood changes, or hunger are not blunted. In Februarythe FDA and EMA stated that after reviewing a number of clinical trials and animal studies, the current data does not support an increased risk of pancreatitis and pancreatic pwckage in patients receiving incretin mimetics. Growth hormones, such as somatropin, may byrureon insulin sensitivity, leading to glucose intolerance and loss of blood glucose control.
Typically, blood glucose could be affected, which, in turn, may affect the clinical response to antidiabetic agents. Exenatide does not increase insulin activity in nondiabetics. Moderate New onset diabetes mellitus, exacerbation of diabetes mellitus, and hyperglycemia due to insulin resistance have been reported with use of protease inhibitors.
Double-check dosage prior to administration. Because exenatide has a short elimination half-life and a high molecular weight, if it is excreted in human milk, it will probably be in low concentrations. In diabetic patients, the metabolic effects of androgens may decrease blood glucose and, therefore, may decrease antidiabetic agent dosage requirements.
Minor Carbonic anhydrase inhibitors may alter blood sugar.
As determined from ex vivo study of healthy, term, human placentas, the passage of exenatide through the placenta appears minimal; the fetal: Safety and effectiveness of exenatide have not been established in children or adolescents under 18 years of age.
Exenatide is cleared primarily by the kidney. Patients receiving this combination should be monitored for changes innsert glycemic control.